Kohl S, Charlebois E D, Sigouroudinia M, Goldbeck C, Hartog K, Sekulovich R E, Langenberg A G, Burke R L
Department of Pediatrics, San Francisco, CA 94110, USA.
J Infect Dis. 2000 Jan;181(1):335-9. doi: 10.1086/315208.
The humoral response to a herpes simplex virus (HSV) type 2 subunit vaccine containing recombinant glycoproteins B (gB2) and D (gD2) was tested in 3 groups of patients. These included HSV-seronegative, HSV-1-seropositive, and HSV-2-seropositive individuals. There were excellent antibody responses, as measured by gB2- and gD2-specific ELISAs and HSV-2 neutralization assays. However, in 2 HSV-2 antibody-dependent cellular cytotoxicity (ADCC) assays, there were relatively low antibody responses, especially among HSV-seronegative individuals. The low ADCC responses may be associated with the poor efficacy of this vaccine observed in clinical trials.
在3组患者中测试了对含有重组糖蛋白B（gB2）和D（gD2）的2型单纯疱疹病毒（HSV）亚单位疫苗的体液反应。这些患者包括HSV血清阴性、HSV-1血清阳性和HSV-2血清阳性个体。通过gB2和gD2特异性酶联免疫吸附测定（ELISA）以及HSV-2中和试验测量，抗体反应良好。然而，在2项HSV-2抗体依赖性细胞毒性（ADCC）试验中，抗体反应相对较低，尤其是在HSV血清阴性个体中。ADCC反应较低可能与该疫苗在临床试验中观察到的疗效不佳有关。
